Roche subsidiary Genentech has entered an exclusive worldwide research collaboration and license agreement with UK-based Astex Pharmaceuticals, paying USD 25 million upfront for access to a small molecule discovery program targeting a cell-cycle-dependent regulator in breast cancer. The deal, which carries potential milestone payments exceeding USD 490 million plus tiered royalties, positions Genentech as the sole driver of preclinical and clinical development for any candidates that emerge. For Astex — a wholly owned subsidiary of Japan-based Otsuka Pharmaceutical Co., Ltd. since 2013 — the agreement is the latest in a string of Big Pharma partnerships built on its fragment-based drug discovery (FBDD) platform, which has already yielded three approved oncology drugs through prior collaborations.
Under the deal terms, Astex grants Genentech an exclusive license to lead compounds from its existing breast cancer discovery program and will collaborate with Genentech scientists during the lead optimization phase to advance compounds toward preclinical candidate nomination. Once a candidate is identified, Genentech assumes sole responsibility for all subsequent development and global commercialization. Milestone payments span preclinical, clinical, regulatory, and sales triggers; individual values were not disclosed. Royalty rates were not specified beyond a tiered structure.
Deal context
The collaboration is directed at a "key cell-cycle-dependent regulator" in breast cancer — a target described only in general terms in the announcement, without specifying whether it is a CDK or a distinct cell-cycle node such as WEE1, PKMYT1, or aurora kinase. Astex's FBDD approach screens libraries of low-molecular-weight chemical fragments against a biological target, identifying weak binding interactions that are then iteratively grown and optimized into potent lead compounds. The method is particularly suited to targets where conventional high-throughput screening yields poor-quality hits, and Astex has described it as enabling access to novel binding sites.
As per the press release, the program originated from a collaborative project with Newcastle University and Cancer Research Horizons, a lineage that mirrors Astex's earlier MDM2 antagonist ASTX295, which was in-licensed by Mosaic Therapeutics in April 2025 along with ERK1/2 inhibitor ASTX029. That deal used equity rather than cash as primary currency — Astex received a 19% stake in Mosaic plus a further 3% contingent on clinical milestones — illustrating how deal currency varies with counterparty scale. The Genentech transaction, by contrast, is a pure cash-plus-milestones structure with no equity component, consistent with a large-cap licensee absorbing all downstream risk.